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ABSTRACT  
 
BACKGROUND Although people who inject drugs (PWID) are an important group to 
receive Hepatitis C Virus (HCV) antiviral therapy, initiation onto treatment remains low. 
Concerns over reinfection may make clinicians reluctant to treat this group.  We examined 
the risk of HCV reinfection among a cohort of PWID (encompassing all those reporting a 
history of injecting drug use) from Scotland who achieved a sustained virological response 
(SVR).  METHODS Clinical and laboratory data were used to monitor RNA testing among 
PWID who attained SVR following therapy between 2000-2009.  Data were linked to 
morbidity and mortality records.  Follow-up began one year after completion of therapy, 
ending on 31
st
 December 2012.  Frequency of RNA testing during follow-up was calculated 
and the incidence of HCV reinfection estimated. Cox proportional hazards regression was 
used to examine factors associated with HCV reinfection.  RESULTS Among 448 PWID 
with a SVR, 277 (61.8%) were tested during follow-up, median 4.5 years; 191 (69%) 
received one RNA test and 86 (31%) received at least two RNA tests.  There were seven 
reinfections over 410 person years generating a reinfection rate of 1.7/100py (95%CI 0.7-
3.5).  For PWID who had been hospitalised for an opiate or injection related cause post SVR 
(11%), the risk of HCV reinfection was greater [AHR=12.9, 95%CI 2.2-76.0, p=0.002] and 
the reinfection rate was 5.7/100py (95%CI 1.8-13.3).  CONCLUSION PWID who have been 
tested, following SVR, for HCV in Scotland appear to be at a low risk of reinfection. Follow-
up and monitoring of this population is warranted as treatment is offered more widely.  
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ABBREVIATIONS PWID, People who inject drugs; HCV, Hepatitis C virus; SVR, 
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1. INTRODUCTION 
The Hepatitis C virus (HCV) is one of the main causes of liver disease resulting in over 
350,000 deaths per year worldwide (Perz et al., 2006).  In resource-rich countries, the main 
route of HCV transmission is through injecting drug use.  An estimated 16 million people 
currently inject drugs worldwide (Mathers et al., 2008) and the majority (>60%) have been 
infected with HCV (Nelson et al., 2011).  Despite favourable treatment outcomes among, and 
indeed guidelines (EASL, 2014) recommending prioritisation for, people who inject drugs 
(PWID) (Aspinall et al., 2013), initiation onto treatment in this population remains low 
(Iversen et al., 2014).  The risk of HCV reinfection following a sustained viral response 
(SVR) among this group remains a concern, causing reluctance among some clinicians to 
treat these individuals.  Several studies have considered HCV reinfection among PWID 
following SVR (Dalgard et al., 2007; Backmund et al., 2004; Currie et al., 2008; Grebely et 
al., 2010; Grebely et al., 2012; Grady et al., 2012) and, in a meta-analysis, Aspinall et al. 
(2013) estimate the rate of HCV reinfection following SVR to be 2.4/100 PY among 131 
people who use drugs (PWUD) and 6.4/100 PY among 45 active PWID.  Uncertainty around 
these estimates remains due to the small sample sizes involved and the predominant focus on 
harm reduction and substitution therapy in follow-up PWID studies.   
In Scotland there has been a 2.7-fold increase in the number of people initiated on 
therapy between 2007 (N=470) and 2014/2015 (N=1,270), related to the sustained financial 
investment by the Scottish Government in the treatment of hepatitis C (Scottish Government 
Health Department 2006, 2008 and 2011; Health Protection Agency, 2015).  The proportion 
of treatment initiates with a history of injecting drug use has also increased from 65% to 83% 
over the same period (Health Protection Agency, 2015).  With the new ‘patient friendly’ 
therapies in our midst (involving short treatment duration, clearance rates of 90% and higher, 
simple oral-only regimens and minimal side effects), the potential to expand treatment further 
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in this high risk population is significant. Guidelines state that following SVR, PWID who 
continue to practise behaviours that put them at risk of reinfection, should be tested annually 
for HCV RNA (EASL, 2014).  However, little is known on the extent of testing and 
reinfection among patients following SVR attainment.  To gain a better understanding of the 
potential risk of reinfection among those who have reported a history of injecting drugs, we 
adopted a novel record-linkage approach of retrospective national HCV clinical and test data 
to uniquely investigate HCV testing practice following SVR and examine the incidence of 
HCV reinfection, and associated risk factors, among PWID in Scotland. 
 
2. METHODS 
2.1 Study population and data sources 
This retrospective cohort includes individuals who were diagnosed with chronic hepatitis C 
and attained a SVR after commencing therapy between 1
st
 January 2000 and 31
st
 December 
2009, in one of four large health boards in Scotland (Greater Glasgow & Clyde, Grampian, 
Lothian or Tayside; representing 73% of new HCV diagnoses in Scotland from 2002-2012), 
and who reported injecting drug use as a risk factor for their HCV infection (n=565570).  A 
sustained viral response is associated with viral clearance and is defined as undetectable HCV 
RNA (i.e. negative RNA) six months after completion of antiviral therapy.  It is not known if 
individuals continued to inject during study follow-up, however they will be referred to as 
PWID from this point onwards.  The cohort were identified from the Scottish HCV clinical 
database, held at Health Protection Scotland, which contains demographical, clinical and 
virological information on all patients who have ever attended a HCV treatment clinic in 
Scotland. Key data such as risk information, genotype (where available), cirrhotic state, start 
and end dates of antiviral therapy, treatment regime and treatment centre are held on this 
system.   
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 To identify RNA test records for our study cohort, the Scottish HCV test database, 
also held at Health Protection Scotland, was used. Retrospective laboratory test data from the 
four largest health boards in Scotland (Greater Glasgow & Clyde, Grampian, Lothian and 
Tayside) are stored in the HCV test database (Shaw et al., 2003; McLeod et al., 2014).  Test 
data were available from 1
st
 January 1999 to 31
st
 December 2012 and included specimen 
date, test results, demographic information and additional details relating to the test.  PWID 
with a SVR were deterministically linked to the HCV test databases, using exact matching of 
patient identifiers; sex, date of birth, first initial and the soundex code of the surname.   
The adopted time frames described above, allowed us to systematically search for a 
positive RNA test prior to treatment and a negative RNA test within 3-12 months post 
completion of therapy (the RNA test closest to 6 months post completion of therapy was 
regarded as the SVR test) for each individual in the cohort.  Patients who did not have a 
positive RNA test prior to treatment or a negative RNA test within 3-12 months of 
completing therapy, were excluded (n=206125).  These criteria ensured that individuals in 
the cohort had a history of injecting drug use and cleared their HCV infection after successful 
treatment.    
The cohort was probabilistically linked to hospital admission data to identify 
injection-related hospital episodes, and mortality data to censor our analysis at death.  These 
data are held by colleagues at Information Services Division.  Hospital admission and 
discharge dates, admission type, details on patient condition (as classified under ICD-9 & 
ICD-10), date of death and cause of death (as classified under ICD-9 & ICD-10) were 
extracted.  We specifically looked for hospital admissions with ICD codes relating to opiate 
and/or injecting drug use, as an indicator of continued injecting drug use, post SVR;  the 
same admission codes described by Valerio et al. (2015)  are applied here and relate to opiate 
use: mental and behavioural disorders due to opiate misuse (ICD-10: F11), poisoning due to 
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opium (ICD-9: 965.0; ICD-10: T40.0), poisoning due to heroin (ICD-10: T40.1),  accidental 
poisoning due to heroin (ICD-9: E8500; ICD-10: X42.4) accidental poisoning due to opium 
(ICD-10: X42.9), intentional self-poisoning by exposure to opium (ICD-10: X62.9),  opiate 
dependence (ICD-9: 3040),  non-dependent opiate use (ICD-9: 3055), finding opiates in 
blood (ICD-10: R781), and injecting behaviour; endocarditis (ICD-9: 421.0; ICD-10: I33), 
deep vein thrombosis (ICD-9: 451, 453 ; ICD-10: I80), cellulitis /abscesses (ICD-9: 682; 
ICD-10: L02, L03). 
Study follow-up began one year after completion of therapy, to ensure that RNA tests 
relating to SVR were not included in the analysis, and ended on 31
st
 December 2012. 
Individuals who were known to have died prior to the start of follow-up were excluded 
(n=2).  
 
2.2 Statistical analysis 
Deterministic record linkage, data manipulation and statistical analyses were performed using 
statistical software packages R, version 3.03 (R Core Team 2014), Stata, release 9 (StataCorp 
2005.  College Station, TX, USA) and database system PostgreSQL, version 1.14.3 (The 
pgAdmin Development Team, 2012). 
 
2.2.1 Frequency of, and factors associated with HCV RNA testing  
The frequency of RNA testing during study follow-up was investigated and Cox proportional 
hazard regression was used to examine differences between those who did and did not receive 
a RNA test.  Time at risk begins one year after completion of therapy (to allow up to 9 
months for SVR eligibility and then up to three months to receive that SVR test) and ends at 
earliest date of first RNA test, date of death or 31st December 2012.  Kaplan Meier survival 
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analysis was used to estimate the cumulative proportion tested for RNA within the first three 
years of follow-up post SVR.  
 
2.2.2 Incidence rate of, and factors associated with Reinfection  
All PWID who received at least one RNA test during study follow-up were considered in this 
analysis. HCV reinfections were defined as a positive RNA result during study follow-up and 
the time of reinfection was estimated to be the midpoint between the last negative and the 
first positive RNA results.  Time at risk began one year after completion of therapy and ends 
at earliest date of reinfection, last negative RNA test (for PWID who are not reinfected) or 
date of death.  The incidence of HCV reinfection was expressed in terms of person years.  
Associated risk factors were analysed using Cox proportional hazards regression. 
 
3. RESULTS 
3.1 Study cohort 
Between January 2000 and December 2009, 448 PWID were eligible for inclusion into the 
study cohort.  The majority were men (77%) aged greater than 35 years old at the start of 
treatment (mean age 38 years with standard deviation ± 8 years, range 18-66 years) and most 
individuals commenced therapy between 2006 and 2009 (66%).  Pegylated interferon (Peg 
IFN) and Ribavirin was the treatment regime for 97% of the cohort.  Thirty-one PWID (7%) 
were cirrhotic at the start of treatment and 95% were treatment naive.  In terms of potential 
risk behaviour, 33% and 10% of PWID had been admitted to hospital with an opiate or 
injection related cause pre treatment and during follow-up respectively.  The mean follow-up, 
from cohort entry to 31
st
 December 2012, was 4.5 years (range 181 days - 11.9 years) 
involving a total of 2,014 person years. 
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3.2 Frequency of, and factors associated with HCV RNA testing  
The frequency of HCV RNA testing during follow-up is described in Figure 2.  Two 
individuals died during the first year of the follow-up period leaving 446 PWID available for 
testing, of which only 214 were tested (48%).  The proportion of PWID tested continued to 
decrease during follow-up, with ≤10% receiving a RNA test during the 4th and subsequent 
years of follow-up.  
Follow-up time to first RNA test (Table 1), was 910 person years (average 2.0 years, 
range 1 day - 9.8 years), during which 277 PWID received at least one RNA test and 413 
RNA tests were carried out during the study period.  The Kaplan Meier estimate of the entire 
cohort tested for RNA within the first three years of follow-up was 59.9% (95% CI 55.2-
64.6).  Strong associations with the frequency of RNA testing were observed among PWID 
who; were cirrhotic at the start of therapy [AHR=1.86 with 95% CI 1.15-3.00], commenced 
therapy in recent years i.e. from 2003 to 2005 [AHR=0.67 with 95% CI 0.43-1.03] and from 
2006 to 2009 [AHR=0.50 with 95% CI 0.33-0.76] relative to those who commenced therapy 
between 2000-2002. 
 
3.3 Incidence rate of, and factors associated with Reinfection  
Of the 277 PWID who had at least one RNA test during follow-up, there were seven (2.5%) 
reinfections (Table 2). A total of 28 RNA tests were carried out among these individuals.  Of 
the seven reinfections, four had only one positive RNA test during follow-up, two individuals 
had two positive RNA tests and one individual had three consecutive positive RNA tests.  
Genotype data was available for all primary infections and four reinfections.  For all four 
cases where the genotype of the reinfection was known, a genotype switch was observed 
when compared with the primary infection.  
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The total follow-up time in our reinfection analysis was 410 person years (average 1.5 
years, range 1 day - 8.9 years).  The overall estimated incidence rate of reinfection was 
1.71/100 PY [95% CI 0.69-3.52]. The incidence of reinfection among PWID who had an 
opiate-related hospitalisation pre treatment, 3.36/100 PY (95% CI 1.09-7.83), was 4 times 
larger than in those who had not, 0.77/100PY (95% CI 0.09-2.77) [AHR=2.44 with 95% CI 
0.41-14.37].  The incidence of reinfection among those who were admitted to hospital with 
an opiate or injection related cause during study follow-up was 5.68/100 PY (95% CI 1.84-
13.26); substantially greater than those who were not admitted (0.62/100 PY) [AHR=12.89 
with 95% CI 2.18-73.21]. 
 
4. DISCUSSION 
Data on the incidence rate of HCV reinfection following treatment induced viral clearance 
among PWID is limited.  A recent meta-analysis identified five prospective studies where 
PWID were followed up after successfully completing treatment for their HCV infection 
(Aspinall et al., 2013).  With a combined sample size of 131 individuals, the incidence of 
HCV reinfection was estimated to be reasonably low at 2.4/100 PY among people who had 
ever injected drugs (includes individuals who have ceased injecting and active injectors) and 
6.4/100 PY among people who reported injecting drug use post SVR.  Using a unique 
retrospective record linkage study design, we estimate similar rates of reinfection to be 
1.7/100 PY among people who have ever injected and 5.7/100 PY among those with 
behaviours suggesting ongoing drug use (based on hospital admission data).  Higher 
reinfection rates have been reported among PWID in the prison setting; 5.3/100 PY overall 
and 12.5/100 PY among active PWID (Marco et al., 2013).  The risk of reinfection found 
among PWID who were hospitalised with an opiate or injection related cause during the 
study follow-up period [AHR 12.89 with 95% CI 2.18-76.04] was greater than that found 
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among those who were not hospitalised; suggesting this measure is a reasonable proxy for 
continued injecting drug use and risk behaviour in this group.  However, since we did not 
have information on current injecting status during follow-up, these results may not be 
generalisable to all or active PWID. 
Drawing on data on the average incidence of HCV infection among active PWID in 
the Scottish community, estimated to be 10.0/100 PY across the 2008/09, 2010 and 2011/12 
sweeps of the Needle Exchange Surveillance Initiative (University of the West of Scotland et 
al, 2008/2009; 2010; 2011/2012), would suggest that individuals in this study, who have 
undergone treatment and successfully cleared their infection, had in comparison fewer 
injecting risk behaviours post SVR; it’s plausible that many in the cohort had indeed ceased 
injecting prior to commencement of treatment.  However there remains at least a minority of 
individuals who continue to behave in a way that puts them at risk of becoming reinfected, 
also observed by Valerio et al. (2015), and these individuals must be identified and closely 
monitored via periodic RNA testing as suggested in the EASL guidelines (EASL, 2014).  Our 
data suggest that the frequency of RNA testing, post-SVR, among successfully treated PWID 
has decreased over time; PWID treated recently i.e. 2006-2009, were 50% less likely to 
receive an RNA test when compared with those treated during 2000-2002.  To adhere to 
recent clinical guidelines on annual HCV re-testing for those at risk (EASL, 2014), a 
coordinated approach (involving practitioners in specialist care, general practice and 
addiction services) will undoubtedly be required to ensure an increase in testing among this 
group, and a more comprehensive assessment of the risk of HCV reinfection will be possible.     
This study has the following limitations. Firstly, the reinfection studies reviewed by 
Aspinall et al. (2013) used prospective cohort designs, which have the advantage of closely 
monitoring individuals over time and frequent testing of HCV RNA is possible.  In general, 
PWID are not routinely tested for RNA post SVR and 38.2% of the cohort (N=171) were 
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never tested during follow-up in this study.  Of those who were tested, 69% received just one 
RNA test.  This may be an accurate representation of the frequency of RNA testing post SVR 
in Scotland however we must acknowledge that the linkage process is not perfect and RNA 
tests may not have been identified due to lack of identifiers in the HCV test database (12.9% 
of HCV test records do not have complete identifiers i.e. sex, date of birth, soundex code of 
surname and first initial, which are required for deterministic linkage) and therefore RNA 
testing among this group may be underestimated (Kendrick and Clarke, 1993).   
Ideally two consecutive positive RNA tests would be required to confirm reinfection 
(Scottish Intercollegiate Guidelines Network, 2013). In this analysis, at least two positive 
RNA tests were identified during follow-up for three reinfections, however due to limited 
testing data, the classification of a reinfection relied on one positive RNA test for the 
remaining four reinfections.  Among four PWID with possible reinfection (including one 
with only one positive RNA test), a genotype switch was observed between the primary and 
secondary infections giving further support to these being true reinfections.  Hara et al. 
(2015) have shown that small levels of HCV can persist for years following treatment 
induced viral clearance (based on interferon based therapy) and therefore ‘reinfections’ from 
a new virus may actually be late relapses due to the original strain detected before treatment.  
Sequence typing would be preferable to prove reinfection beyond doubt; however sequence 
data were not available in this analysis.  Approximately 38% of the eligible cohort (171 out 
of 448, Figure 1.) were not included in the analysis of reinfection because HCV RNA tests 
could not be identified during follow-up.  Similar to those who were included, 10% of these 
individuals had been admitted to hospital with an opiate or injection related cause during 
follow-up, therefore the reinfection rate for this group is likely to be similar to that presented.  
However, hospital admission data was not available for 122 PWID who were excluded from 
the study and estimates of ongoing risk behaviour in this group is unknown.  
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Of the four reinfections where a genotype switch was observed, two were also 
successfully treated for the second time and cleared their reinfection during follow-up.  Both 
individuals were treated with Peg IFN and Ribavirin for the initial infection and reinfection.  
Treatment courses are reasonably long and side-effects associated with Peg IFN therapy can 
be severe (Scottish Intercollegiate Guidelines Network, 2013) and may be viewed by some as 
a deterrent against risk behaviours associated with reinfection.  The new therapies coming 
onto the market are highly effective (~90% clearance rate) (Scottish Medicines Consortium, 
2015), follow simple one pill regimens and are interferon free therefore have minimal side 
effects.  Widespread use of these new therapies will take time due to the high associated 
costs; however having access to a simple oral regimen with a high chance of clearance may 
not dissuade people against risking reinfection in the future.  A degree of risk complacency 
has been observed in the context of HIV, where there is some evidence suggesting that young 
men who have sex with men (MSM), who had never tested for HIV or had last tested HIV 
negative, are less concerned about becoming infected with HIV because of antiretroviral 
therapy (ART), and are therefore more likely to engage in risk behaviours associated with the 
acquisition of HIV (MacKellar et al. 2011a, 2011b).   
Looking to the future, the frequency of RNA testing among PWID will increase if the 
new EASL guidelines (EASL, 2014) are adopted i.e. annual RNA testing among those who 
continue to inject post SVR, and it remains to be seen how this will impact on the number of 
HCV reinfections identified.  Using mathematical modelling Vickerman et al. (2012) explain 
that long time intervals (>3 months) between testing may underestimate reinfection rates; the 
model considered spontaneous resolvers only, but this may also be applicable to those who 
clear their infection following successful antiviral therapy.  Therefore, even if annual testing 
among PWID following successful treatment becomes routine, we may still underestimate the 
number of individuals who are reinfected due to the length of time between tests.  
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4.1 Conclusions and recommendations 
This study applied a novel approach to estimate HCV reinfection following treatment induced 
viral clearance among a group of individuals reporting injecting drug use as a risk factor for 
their initial infection.  The results highlight a possible issue in terms of the lack of routine 
testing among PWID post SVR; however it is hoped that more frequent testing will occur in 
light of the new EASL guidelines (EASL, 2014) and in turn this will help identify HCV 
reinfections in a timely manner.  Using opiate and/or injection related hospital admissions as 
a proxy for continued injecting drug use post SVR, we found that a reasonable proportion (at 
least 10%) of individuals continue to inject at a high intensity.   For individuals who are 
known to have ever injected drugs, provision of harm reduction services such as education on 
risk behaviours, needle and syringe exchange programmes and opiate substitution therapy 
should be available alongside and following treatment.  Reinfection rates among these 
individuals is comparable to other estimates reported in the literature, however we are the 
first to adopt record linkage techniques and use “real world“ administrative health data to 
tackle this question.  These data support the consensus view that the rate of reinfection among 
this population, on the whole, is low.  Reinfection should not therefore be seen as a barrier to 
treating PWID with antiviral therapy.   
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Table 1. Relative risk of receiving at least one HCV RNA test among PWID during study 
follow-up, where time at risk begins one year after completion of therapy and ends at earliest 
date of first RNA test, date of death or 31st December 2012. 
Table 2. Detection of HCV reinfection among PWID who have received at least one RNA 
test during study follow-up, where time at risk begins one year after completion of therapy 
and ends at earliest date of reinfection (midpoint between last negative RNA test and first 
positive RNA test), last negative RNA test (for PWID who are not reinfected) or date of 
death.  
Fig 1. Schematic diagram of study cohort. 
Fig 2.  Frequency of HCV RNA testing during study follow-up.  Total number of PWID in 
each year of study follow-up is given in brackets (excluding those who died during or prior to 
that year). 
